ACBD5

Across TCGA pan-cancer cohorts, ACBD5 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of ACBD5’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where ACBD5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACBD5 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

BLCA, STAD, and KICH are the cancer types where ACBD5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACBD5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+0.876	<.001	10	view →
STAD	Male	II,III,IV	+1.159	<.001	9	view →
KICH	Female	All	−1.139	<.001	7	view →
THCA	Male	All	−0.752	<.001	7	view →
KIRC	Male	All	−0.436	<.001	6	view →
BRCA	All	II,III,IV	+0.341	<.001	6	view →
LUAD	Male	II,III,IV	+0.559	.002	3	view →
COAD	Male	II,III,IV	+0.423	.026	2	view →
PRAD	All	All	+0.323	.006	2	view →
LUSC	Male	All	−0.222	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

ACBD5–BLCA

Open the BLCA breakdown →